LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome
暂无分享,去创建一个
M. Look | E. Berns | L. Dirix | S. V. van Laere | M. Jansen | K. Ruigrok-Ritstier | J. C. Helmijr | Diana E. Ramirez-Ardila
[1] J. Tyson,et al. Endocrine resistance in breast cancer – An overview and update , 2015, Molecular and Cellular Endocrinology.
[2] M. Bentires-Alj,et al. Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. , 2015, Molecular cell.
[3] Wei Gao,et al. Hsa-miR-301a-3p Acts as an Oncogene in Laryngeal Squamous Cell Carcinoma via Target Regulation of Smad4 , 2015, Journal of Cancer.
[4] Shu-peng Chen,et al. MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets , 2015, BMC Cancer.
[5] M. Hou,et al. The Immune Regulator VTCN1 Gene Polymorphisms and Its Impact on Susceptibility to Breast Cancer , 2015, Journal of clinical laboratory analysis.
[6] Yonglei Liu,et al. miR-449a promotes liver cancer cell apoptosis by downregulation of Calpain 6 and POU2F1 , 2015, Oncotarget.
[7] M. Todaro,et al. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance , 2015, Cell Death and Disease.
[8] M. Dowsett,et al. Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Ellis,et al. Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.
[10] Michael G. Kharas,et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.
[11] Wenxin Qin,et al. LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells , 2015, Medical Oncology.
[12] N. Urban,et al. Validation of LRG1 as a Potential Biomarker for Detection of Epithelial Ovarian Cancer by a Blinded Study , 2015, PloS one.
[13] Guangshun Wang,et al. 非小细胞肺癌患者尿蛋白质组差异表达分析 , 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[14] M. Sussman,et al. The Concentrations of EGFR, LRG1, ITIH4, and F5 in Serum Correlate with the Number of Colonic Adenomas in ApcPirc/+ Rats , 2014, Cancer Prevention Research.
[15] Jaana M. Hartikainen,et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium , 2014, Human molecular genetics.
[16] E. Diamandis,et al. Deciphering the peptidome of urine from ovarian cancer patients and healthy controls , 2014, Clinical Proteomics.
[17] W. Xu,et al. LRG1 is an independent prognostic factor for endometrial carcinoma , 2014, Tumor Biology.
[18] Lei Wang,et al. Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling. , 2014, Gene.
[19] J. Foekens,et al. Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. , 2013, Cancer research.
[20] Andrea Sottoriva,et al. The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.
[21] S. Sleijfer,et al. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen , 2013, Breast Cancer Research and Treatment.
[22] Stefano Volinia,et al. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer , 2013, Proceedings of the National Academy of Sciences.
[23] M. Dowsett,et al. Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance , 2013, Clinical Cancer Research.
[24] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[25] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[26] N. Traficante,et al. The Australian Ovarian Cancer Study , 2012, Hereditary Cancer in Clinical Practice.
[27] Carme Camps,et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.
[28] W. Miller,et al. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole , 2010, Breast Cancer Research.
[29] Paul Ellis,et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.
[30] K. Nakayama,et al. Phospholipase C-related but Catalytically Inactive Protein Is Required for Insulin-induced Cell Surface Expression of γ-Aminobutyric Acid Type A Receptors* , 2009, The Journal of Biological Chemistry.
[31] K. Nakayama,et al. Involvement of Phospholipase C-Related Inactive Protein in the Mouse Reproductive System Through the Regulation of Gonadotropin Levels1 , 2009, Biology of reproduction.
[32] Asli Silahtaroglu,et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.
[33] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[34] Lei Wang,et al. Upregulated microRNA-301 a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt / β-catenin signaling ☆ , 2013 .
[35] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .